Read the Canadian Cancer Trials Group story on the launch of the ALC.10 (MM1OA-EA02) study. Presented in connection with the myeloMATCH program, the trial compares standard treatment for FLT3-mutated acute myeloid leukemia (AML) with a novel approach incorporating gilteritinib using two different treatment schedules in older and less fit patients. The study focuses on improving outcomes for this patient population and is led in Canada by Dr. David Sanford, hematologist at BC Cancer.